Rare Case of Malignant Fibrous Histiocytoma of the Bladder Associated with Microinfiltrating Transitional Cell Carcinoma

1998 ◽  
Vol 65 (1_suppl) ◽  
pp. 89-92
Author(s):  
F. Di Nuovo ◽  
O. Privitera ◽  
R. Bonacina ◽  
G. Catania ◽  
M. Sironi ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Malignant Fibrous Histiocytoma ◽  
Carcinoma In Situ ◽  
Rare Case ◽  
Fibrous Histiocytoma ◽  
Transitional Cell ◽  
Soft Tissue Tumours

Although malignant fibrous histiocytoma is the most common among soft tissue tumours in adults, its origin in the bladder is extremely rare. Only 17 cases have been reported so far. We present the case of an 86-year-old patient who, following clinical and instrumental examination for a large bladder growth, underwent partial cystectomy. The histopathological exam showed a neoplastic mass, while immunohistochemical findings indicated a malignant fibrous histiocytoma. A transitional cell carcinoma in situ with microinfiltration of the lamina propria was also observed near the above tumour.

scholarly journals Does Urine Cytology Still have a Role?

2005 ◽  
Vol 72 (3) ◽  
pp. 301-306
Author(s):  
M. Ciaccia ◽  
R. Bertoloni ◽  
F. Pinto ◽  
A. Calpista ◽  
P.F. Bassi
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
High Sensitivity ◽  
Urine Cytology ◽  
Low Grade ◽  
New Methods

Urine cytology is a reliable and well known tool in the diagnosis and follow-up of patients with transitional cell carcinoma even if it has high sensitivity only in high grade tumors and carcinoma in situ. In order to improve sensitivity of this test in patients with low grade tumors, new methods such as cytometry, microsatellite assays, Immunocyt®, fuorescence in-situ hybridization and Thin-Prep monolayer have been developed. These new assays will be able to increase the cytology detection rate and to predict the outcome of transitional cell carcinoma.

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER:

2000 ◽  
pp. 1124-1129 ◽  
Author(s):  
DONALD L. LAMM &NA; &NA; ◽  
BRENT A. BLUMENSTEIN ◽  
JOHN D. CRISSMAN ◽  
JAMES E. MONTIE ◽  
JAMES E. GOTTESMAN ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
Bacillus Calmette Guerin ◽  
Carcinoma Of The Bladder

Bacillus Calmette–Guérin (BCG) Immunotherapy for Recurrent Noninvasive Transitional Cell Carcinoma of the Bladder

2021 ◽  
pp. 135-140
Author(s):  
Vikram M. Narayan
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
High Grade ◽  
Bacillus Calmette Guerin ◽  
Urothelial Cell Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Disease Specific

This study summarizes the landmark study assessing the value of maintenance intravesical Bacillus Calmette Guerin (BCG) to reduce the risk for recurrence or progression of high-grade superficial or carcinoma in situ (CIS) transitional cell carcinoma of the bladder. The trial randomized patients with completely resected noninvasive urothelial cell carcinoma at high risk of recurrence to BCG induction alone versus BCG induction plus maintenance therapy in the form of six weekly treatments. The study found that maintenance BCG reduces disease-specific recurrence and may also reduce the rate of disease progression.

Sign in / Sign up

Export Citation Format

Share Document